About SynDevRx

SynDevRx has offices in Scottsdale Arizona and Cambridge Massachusetts. Our team has decades of oncology drug and polymeric drug development expertise. Our goal is to develop novel compounds that target MetAP2 in a formulation-dependent way, and commercialize them through partnerships with industry leaders.

Here at SynDevRx, we believe that success comes from a balanced combination of leading technology and talented people with synergistic skills. The combination of our best-in-class technology, world Key Opinion Leaders in clinical oncology, senior drug development professionals and creative marketing executives with fresh perspectives delivers high value solutions to patients and investors alike.

Unlocking The Value Of MetAP2

MetAP2 is a unique, clinically recognized target, that has researchers and scientists' attention.  It was recently announced that MetAP2 is possibly a newly-defined oncogene, thereby elevating its importance with respect to cancer treatments.  Yet, until this generation of technology, finding a suitable compound that safely and selectively targets MetAP2 has proven elusive.

Combining a well characterized molecule clinically proven to have exclusive, high affinity for MetAP2 with a nano-transport non-degradable polymer is a rational approach to drug delivery.  The fact that each of these components has been in humans previously greatly reduces the risks while increasing the likelihood of success.